摘要
目的:观察分析门冬胰岛素注射液(诺和锐)与生物合成人胰岛素注射液(诺和灵-R)在妊娠期糖尿病治疗中的疗效及安全性。方法:从我院收治入院的妊娠期糖尿病患者中抽取60例,随机分为观察组与对照组,观察组使用诺和锐进行治疗,对照组使用诺和灵-R进行治疗,对比观察两组患者的疗效及安全性。结果:观察组空腹血糖、餐后2h血糖、血红蛋白含量、胰岛素用量及血糖控制达标时间均明显小于对照组,低血糖出现率低于对照组,差异有统计学意义(P<0.05)。结论:在妊娠期糖尿病的治疗中,诺和锐相比诺和灵-R具有更为显著的临床疗效和更高的安全性,值得进一步推广应用。
Objective：To observe the insulin aspart and Novolin-R in efficacy and safety in the treatment of gestational diabetes mellitus.Methods：Select 60 cases of gestational diabetes patients randomly divided into observation group and control group,the observation group used insulin aspart treatment,the control group used Novolin-R treatment.Results：In the observation group,FPG,2h PPG,HbAlc,insulin dosage and blood glucose control standard time were significantly less than that of the control group,hypoglycemia was lower than the control group,the difference was statistically significant （P〈0.05）.Conclusion：In the treatment of gestational diabetes,insulin aspart than NovolinE-R has a more significant clinical efficacy and high safety.
出处
《中国医药导刊》
2013年第10期1653-1654,共2页
Chinese Journal of Medicinal Guide
关键词
诺和锐
诺和灵-R
妊娠期糖尿病
Insulin aspart
Insulin novolin-R
Gestational diabetes mellitus
